1. Academic Validation
  2. Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells

Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells

  • RSC Med Chem. 2024 Feb 26;15(4):1348-1361. doi: 10.1039/d3md00711a.
Joana R L Ribeiro 1 Nikoletta Szemerédi 2 Bruno M F Gonçalves 1 Gabriella Spengler 2 Carlos A M Afonso 1 Maria-José U Ferreira 1
Affiliations

Affiliations

  • 1 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa Av. Prof. Gama Pinto 1649-003 Lisbon Portugal mjuferreira@ff.ulisboa.pt.
  • 2 Department of Medical Microbiology, Albert Szent-Györgyi Health Center, Albert Szent-Györgyi Medical School, University of Szeged Semmelweis utca 6 H-6725 Szeged Hungary.
Abstract

Multidrug resistance (MDR) remains a challenging issue in Cancer treatment. Aiming at finding Anticancer agents to overcome MDR, the triacetyl derivative (2) of the labdane diterpenoid lactone andrographolide (1) underwent the Michael-type addition reaction followed by elimination, yielding twenty-three new derivatives, bearing nitrogen-containing substituents (3-25). Their structures were assigned, mainly, by 1D and 2D NMR experiments. The MDR reversal potential of compounds 1-25 was assessed, by functional and chemosensitivity assays, using resistant human ABCB1-gene transfected L5178Y mouse lymphoma cells as a model. Several derivatives exhibited remarkable P-glycoprotein (P-gp) inhibitory ability. Compounds 13 and 20, bearing thiosemicarbazide moieties, were the most active exhibiting a strong MDR reversal effect at 2 μM. Some compounds showed selectivity towards the resistant cells, with compound 5 exhibiting a collateral sensitivity effect associated with significant antiproliferative activity (IC50 = 5.47 ± 0.22 μM). Moreover, all selected compounds displayed synergistic interaction with doxorubicin, with compound 3 being the most active. In the ATPase assay, selected compounds exhibited characteristics of P-gp inhibitors.

Figures